Mumbai (Maharashtra) [India], Aug 10 (ANI): India Ratings and Research (Ind-Ra) said on Tuesday that 13.7 per cent y-o-y revenue growth in India's pharmaceutical market during 2021 was led by continued demand normalisation post the high growth months of April and May.
Glaxosmithkline Pharmaceuticals fell 1.75% to Rs 1,489.15 after the company s consolidated net profit tanked 89.6% to Rs 14.33 crore on 4.9% increase in net sales to Rs 813.75 crore in Q4 March 2021 over Q4 March 2020.
Profit before tax (PBT) dropped 64.3% to Rs 63.01 crore in Q4 FY21 from Rs 176.55 crore in Q4 FY20. The Q4 result was declared post market hours yesterday, 18 May 2021.
On a standalone basis, revenue for the quarter came in at Rs 807 crore, recording an underlying growth of 6%. Total income came in at Rs 837 crore as compared to Rs 791 crore for the quarter ended 31st March 2020. PBT (before exceptional) for the quarter at Rs 180 crore, recorded a growth of 9%.
Why the stock of Alkem Labs is a good ‘Buy’
The stock is suitable for long-term investors, given multiple positives and reasonable valuation
Alkem Laboratories, the fifth largest pharma company in India, is a dominant player in acute therapy areas with well-established brands.
The company is ranked number one market share in terms of revenue in anti-infectives. It also has the third largest market share each in gastro-intestinal and pain and analgesics therapies. Over the years, Alkem Labs has held on to or improved its rankings in these areas.
In the chronic segment too, which covers neurology, dermatology, cardiology and anti-diabetics, Alkem Labs, despite smaller presence, has managed to up its market share.